According to Zacks, “Vital Therapies, Inc. is a biotherapeutic company. It is focused on developing a cell-based therapy targeting the treatment of acute liver failure. The Company operates in the United States, Europe, and China. Vital Therapies, Inc. is based in San Diego, California. “
Several other analysts have also recently commented on VTL. Canaccord Genuity set a $10.00 price objective on shares of Vital Therapies and gave the company a buy rating in a research note on Monday, January 2nd. BTIG Research reaffirmed a hold rating on shares of Vital Therapies in a report on Friday, March 10th.
Vital Therapies (NASDAQ:VTL) traded down 2.78% during mid-day trading on Friday, reaching $3.50. The company had a trading volume of 66,550 shares. Vital Therapies has a 12-month low of $3.50 and a 12-month high of $9.25. The firm’s market capitalization is $112.50 million. The firm has a 50-day moving average price of $4.07 and a 200 day moving average price of $4.91.
Vital Therapies (NASDAQ:VTL) last released its earnings results on Tuesday, March 7th. The company reported ($0.37) EPS for the quarter, missing analysts’ consensus estimates of ($0.36) by $0.01. During the same period in the prior year, the business posted ($0.34) EPS. Analysts expect that Vital Therapies will post ($1.51) EPS for the current year.
COPYRIGHT VIOLATION WARNING: “Zacks Investment Research Lowers Vital Therapies Inc (VTL) to Sell” was reported by Community Financial News and is the sole property of of Community Financial News. If you are viewing this news story on another website, it was illegally copied and republished in violation of US & international copyright legislation. The correct version of this news story can be viewed at https://www.com-unik.info/2017/04/21/vital-therapies-inc-vtl-cut-to-sell-at-zacks-investment-research-updated-updated.html.
In other news, Director Muneer A. Satter purchased 3,750,000 shares of the stock in a transaction dated Monday, March 27th. The shares were purchased at an average price of $4.00 per share, with a total value of $15,000,000.00. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 29.88% of the company’s stock.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. State Street Corp raised its stake in shares of Vital Therapies by 6.0% in the fourth quarter. State Street Corp now owns 328,091 shares of the company’s stock worth $1,427,000 after buying an additional 18,645 shares during the period. Sei Investments Co. acquired a new stake in shares of Vital Therapies during the third quarter worth about $321,000. Finally, Victory Capital Management Inc. acquired a new stake in shares of Vital Therapies during the third quarter worth about $14,214,000. 26.68% of the stock is currently owned by institutional investors.
Vital Therapies Company Profile
Vital Therapies, Inc is a biotherapeutic company. The Company is focused on developing a human hepatic cell-based treatment targeting acute forms of liver failure. Its product candidate, the ELAD System, is an extracorporeal human allogeneic cellular liver therapy designed to allow the patient’s liver to regenerate to a healthy state, or to stabilize the patient until transplant.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
What are top analysts saying about Vital Therapies Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Vital Therapies Inc and related companies.